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Summary Formoterol has a similar onset of effect to salbutamol but a prolonged
duration of action. However, the relative efficacy of the two drugs in acute severe
asthma is not known. This double-blind, double-dummy study compared the safety
and efficacy of the maximum recommended daily dose of formoterol and a predicted
equivalent dose of salbutamol in 88 patients presenting to the emergency department
with acute severe asthma. Patients were randomized to formoterol 54 mg via
Turbuhalers or salbutamol 2400 mg via pressurized metered dose inhaler (pMDI) plus
spacer in three equal doses over 1 h. Following the full dose, mean FEV1 at 75min
increased by 37% for formoterol and 28% for salbutamol (P ¼ 0:18). The maximum
increase in FEV1 over 4 h was significantly greater with formoterol compared with
salbutamol (51% vs. 36%, respectively Po0:05) and formoterol was as effective as
salbutamol at improving symptoms and wellbeing. Both treatments were well
tolerated. Formoterol caused a greater decrease in serum potassium (difference –
0.2mmol/l). In severe acute asthma, bronchodilator therapy with high-dose (54 mg)
formoterol Turbuhaler provided equally rapid improvements in lung function of
greater magnitude over 4 h than high-dose (2400 mg) salbutamol pMDI plus spacer.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
In hospital emergency departments, the primary
therapy for patients presenting with acute severe
asthma is administration of a rapid-acting b2-
agonist within the first hour.1 In these emergencies,
normal doses of short-acting b2-agonists may be
inadequate2 and repeated administration with
higher doses are normally required. Poor or
incomplete responses in the first 1–2 h may result
in hospital admission. In the USA, up to 20% of
patients with a forced expiratory volume in 1 s
(FEV1)o50% predicted normal are admitted follow-
ing emergency room treatment for further observa-
tion and supervision of administration of additional
doses of short-acting b2-agonists.
3 In this situation,
a rapid-acting b2-agonist with a long duration of
action could reduce the need for more frequent
administration of bronchodilator therapy.
Formoterol is a selective b2-agonist with a rapid
onset of effect (p3min) and a long duration of
action (X12 h).4 Formoterol (Oxiss) Turbuhalers is
at least as rapid acting as the short-acting
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b2-agonist, salbutamol, both in stable asthma
5 and
following methacholine-induced bronchoconstric-
tion, a model of acute severe asthma.6 Importantly,
the systemic effects of formoterol are similar in
duration to those of salbutamol.7,8 A comparative
dose–response study, in which patients with stable
asthma received three doses of formoterol via
Turbuhaler or two doses of salbutamol via pressur-
ized metered dose inhaler (pMDI), suggested that
the therapeutic index (the ratio between improve-
ments in FEV1 over decrease in serum potassium
levels) was more favourable for formoterol than for
salbutamol.9
The unique pharmacodynamic properties of for-
moterol coupled with a good safety profile should
allow it to be used to good effect as both
maintenance and reliever therapy. However, few
studies have examined formoterol Turbuhaler as
reliever therapy during an acute exacerbation. To
establish the safety and efficacy of formoterol for
relief of acute exacerbations, it is appropriate to
compare the efficacy and safety of the drug with a
traditional reliever therapy in patients with acute
asthma in an emergency room setting. The favour-
able balance between efficacy and safety of high-
dose formoterol Turbuhaler relative to high-dose
terbutaline Turbuhaler in the treatment of acute
severe bronchoconstriction has been confirmed,10
although similar comparisons with high-dose salbu-
tamol have not been made. Previous studies
suggest that formoterol 4.5 mg Turbuhaler is an
equivalent bronchodilator dose to salbutamol
200 mg pMDI.4,8 The maximum daily dose of for-
moterol approved for use via Turbuhaler without
physician consultation is 54 mg (12 inhalations),
which is predicted to be equivalent to 2400 mg of
salbutamol via pMDI.
Short-acting b2-agonists have often been admi-
nistered by nebulizer in the emergency room.
However, administration via pMDI plus spacer can
produce equivalent bronchodilation with a more
rapid onset and fewer side effects than with a wet
nebulizer.11,12 Turbuhaler has also been shown to be
an equally effective delivery device in an emer-
gency setting.13,14 In a previous emergency depart-
ment study, salbutamol Turbuhaler was shown to be
as safe and effective as a double dose of salbutamol
pMDI plus spacer.13 Similarly, terbutaline Turbuha-
ler increased FEV1 significantly more than the same
dose administered via pMDI plus spacer in patients
with acute severe bronchoconstriction.14
The aim of this 4-h study was to compare the
efficacy and safety of cumulative administered
high-dose formoterol 54 mg (3 18 mg) via Turbuha-
ler with salbutamol 2400 mg (3 800 mg) via pMDI
plus spacer (multiple doses of salbutamol up to
2400 mg in 1 h are recommended by the global
initiative for asthma [GINA] guidelines for treat-
ment of acute severe asthma1) in a defined group of
patients presenting to an emergency room with
acute severe bronchoconstriction.
Methods
Study design and patients
This was a randomized, double-blind, double-
dummy study with parallel groups, conducted at
five centres in Thailand. A local independent ethics
committee approved the protocol before the study
commenced at each centre. Patients (18–67 years)
diagnosed with asthma and presenting to the
emergency department with acute severe bronch-
oconstriction were included in the study if their
FEV1 was 30–60% of predicted normal values for the
healthy non-smoking Thai population15 and, if aged
X50 years, they had a pulse rate X100 beats/min
on presentation as additional evidence of acute
bronchoconstriction (no pulse criterion was set if
o50 years). This criterion was added to ensure
patients with chronic obstructive airways disease
and fixed airway obstructions were not enrolled.
Patients were excluded from the study if they
required transfer to the intensive care unit, or
nebulized or intravenous b2-agonists at the initial
assessment. Patients with oxygen saturation p91%
in room air or a severe cardiovascular disorder were
also excluded from the study. The patients there-
fore did not represent the most severe end of the
spectrum of acute severe asthma.
Within 30min of arrival at the emergency
department, written consent and demographic
data were obtained and patients were randomized
to receive formoterol Turbuhaler (Oxis, AstraZene-
ca, Sweden) or salbutamol pMDI (Baker Norton, UK)
plus spacer (VolumaticTM, GlaxoSmithKline, UK).
Formoterol (4 4.5 mg inhalations [18 mg]) was
administered to patients at 0, 30 and 60min,
to give a total delivered dose of 54 mg, while
salbutamol pMDI plus spacer (4 2 actuations of
100 mg) was given at 0, 30 and 60min for a
total dose of 2400 mg. As a result of the
double-dummy design, subjects were given
placebo from a Turbuhaler or pMDI plus spacer as
appropriate and inhalations were started with
Turbuhaler or pMDI in random order. To make a
comparison between the investigational treat-
ments possible, a single dose of oral prednisolone
(60mg) was not administered until 80min after the
first dose of study drug.
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Assessments
FEV1 was measured by spirometry at baseline (0),
15, 45, 75, 120, 180 and 240min after first
administration of the study drug. At each assess-
ment the highest FEV1 value was recorded from
three manoeuvres, additional manoeuvres to a
maximum of eight were performed if a difference
of greater than 5% was observed between the
two highest values. All centres used the same
type of spirometer, which met the American
Thoracic Society standard, and which were
calibrated to 3% accuracy each day. The
primary efficacy variable was the relative increase
from baseline in FEV1 75min after the first dose
of study drug. Secondary measures of pulmonary
function included, Eaverage the mean area under the
curve (AUC) FEV1 between 75 and 240min (i.e. the
area under the FEV1 time curve divided by the length
of the measurement interval), Emax; maximum FEV1
between 75 and 240min, and FEV1 at 15 and 45min
after the first and second dose of study drug.
At baseline, 75 and 240min, patients evaluated
their asthma symptoms by a visual analogue scale
(VAS), (scoring on a line 10 cm long between end
points scale 0–100, 0 [no symptoms] to 100 [severe
symptoms] in answer to the question ‘‘How is your
asthma now?’’ Study staff assessed the VAS score by
measuring with a metric ruler the distance between
0 and the patient’s mark).
The Acute Asthma Quality of Life Questionnaire
(Acute AQLQ), was modified in collaboration with
the originator of the AQLQ16 to include only 11
items in two domains (symptoms and emotional
function). The Acute AQLQ, assessed health-related
quality of life subjectively at baseline, 75 and
240min. The perceived overall effect of treatment
on patient wellbeing was recorded on a 15-point
scale, 75 and 240min after the first dose of study
drug.
Safety variables were measured at baseline, 15,
45, 75, 120, 180 and 240min during the 4-h study.
Blood pressure was monitored by a standard
sphygmomanometer; blood samples were drawn
for determination of serum potassium; and a 12-
lead electrocardiogram (ECG) was performed,
recorded and assessed for heart rate, sinus rhythm
and QT interval. The QT interval corrected for
heart rate (QTc) was calculated using Bazett’s
formula. Average, maximum and minimum effects
were calculated in the same way as FEV1. Adverse
events (AEs) reported or observed during the
treatment period were also recorded. AEs were
also collected through a question at the end of the
4-h study period ‘‘Have you had any health
problems since you received the study drug?’’.
Statistics
For the spirometry variables, the relative increase
in FEV1 from baseline to 75min was compared
between treatments using a multiplicative analysis
of variance (ANOVA) model with treatment and
centre as fixed factors and baseline FEV1 as a
covariate. Treatment differences for spirometry
variables: FEV1 at 15, 45, 75min average FEV1 and
maximum FEV1 were expressed as a ratio (in per
cent). VAS, Acute AQLQ, overall treatment evalua-
tion and safety variables were compared between
treatments using an additive ANOVA with centre
and treatment as fixed factors and, with the
exception of the overall treatment evaluation,
baseline readings as a covariate. The number of
subjects with treatment failure (requiring addi-
tional medication in the 4-h period or hospitaliza-
tion) was compared using the w2-test. All analyses
followed the intention-to-treat approach and P-
values less than 5% were considered statistically
significant. With 40 patients per group, there was
an 80% chance of detecting a true difference of 17%
in FEV1, assuming a coefficient of variation of 25%.
Results
All 88 patients enrolled in the study were rando-
mized to treatment, 44 were randomized to
formoterol and 44 to salbutamol (Table 1). The
treatment groups were well matched for level of
airway obstruction at entry, FEV1 44% predicted
normal in both groups and before enrolment a
similar number of patients in each treatment group
had taken asthma medication: 64 (73%) inhaled
short-acting b2-agonists, 31 (35%) inhaled gluco-
corticosteroids, 29 (33%) oral b2-agonists, 25 (28%)
xanthines, 5 (6%) systemic glucocorticosteroids, 4
(5%) long-acting b2-agonists (alone or in combina-
tion with inhaled glucocorticosteroids) and 4 (5%)
anticholinergic inhalers. During the study, two
patients discontinued treatment (both in the
formoterol group), one because of protocol devia-
tion and one withdrew consent after 180min for
practical reasons, both were considered in no need
of further treatment.
Efficacy
The mean increase in FEV1 from baseline was higher
in the formoterol group than in the salbutamol
group at all time points (Fig. 1a). The adjusted
mean percentage increase in FEV1 from baseline at
75min was 37% in the formoterol group compared
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with 28% in the salbutamol group. However, the
adjusted mean difference in favour of formoterol
at 75min (7.2% [95% CI: 3.2, 18.7]; P ¼ 0:18) was
not statistically significant nor was the trend in
favour of formoterol significant at early time points
(Table 2). Emax was 51% in the formoterol group and
36% in the salbutamol group. The increase in the
formoterol group was significantly higher than that
after treatment with salbutamol (adjusted mean
difference 11.1% [95% CI: 0.6, 22.8]; Po0:05).
Similarly, Eaverage was 43% in the formoterol group
and 28% in the salbutamol group and was signifi-
cantly higher in formoterol-treated patients (ad-
justed mean difference 11.7% [95% CI: 0.9, 23.6];
Po0:05). The distribution of patients in each
treatment group achieving or not achieving varying
levels of increase in maximum FEV1 can be seen in
Fig. 1b. No treatment failures occurred in either
treatment group.
Subjective symptom score assessments using the
VAS (0–100 scale) decreased during the course of
the study in both formoterol- and salbutamol-
treated patients. Mean baseline scores were 64 in
both groups and they decreased to 7.21 in the
formoterol group and to 10.24 in the salbutamol
group. The difference (3.04) was not statistically
significant. The mean Acute AQLQ score increased
during the study from 2.67–5.88 in the formoterol
group and 2.49–5.69 in the salbutamol group. There
were no significant differences between treat-
ments in the mean Acute AQLQ scores for overall
evaluation or for symptoms and emotion function
domains at 75 or 240min. Patients’ overall treat-
ment evaluation supported these changes with
comparable scores recorded for formoterol and
salbutamol 75min (4.59 and 4.25, respectively) and
240min (5.43 and 5.50, respectively) post-dosing.
Safety
During the 4-h study period, the adjusted mean
minimum serum potassium value was significantly
lower in the formoterol group than in the salbuta-
mol group (3.2 vs. 3.5mmol/l, respectively;
Po0:001) (Fig. 2a). The adjusted mean average
serum potassium value during the study was also
significantly lower in patients treated with for-
moterol compared with salbutamol (P ¼ 0:002;
Table 3).
Both systolic and diastolic blood pressure de-
creased after the first dose of study drug. However,
there were no statistically significant differences
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Table 1 Patient demographics at baseline (means
and ranges).
Formoterol Salbutamol
No. of patients 44 44
Men (n) 14 (32%) 10 (23%)
Age (years) 45 (18–67) 43 (18–61)
SABA use (n) 34 (77%) 30 (68%)
IGCS use (na) 17 (39%) 16 (36%)
IGCS dose at
entry (mg)
853 (400–1600) 881 (300–1200)
FEV1 (l) 1.06 (0.38–1.74) 1.08 (0.47–2.00)
FEV1 (%
predicted
normal)
44 (17–60) 44 (21–59)
Pulse rate
(bpm)
104 (73–137) 101 (60–129)
SaO2 96 (91–100) 97 (91–100)
SABA, inhaled short-acting b2-agonist; IGCS, inhaled
glucocorticosteroid; SaO2, oxygen saturation.
aTotal includes two patients using fluticasone/salmeterol
combination inhaler.
Figure 1 Effect of formoterol and salbutamol treatment
on (a) geometric mean % increase in FEV1 and (b)
distribution of patients achieving various levels of %
change in maximum FEV1 from baseline.
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in blood pressure between treatment groups
(Table 3). No statistically significant differences
were observed between the groups in heart rate
(Table 3). Similarly, there was no statistically
significant difference between treatments in QTc
(Fig. 2b; Table 3).
Both treatments were well tolerated. Ten
patients reported a total of 13 mild AEs. The most
commonly reported AE was palpitation (five in the
formoterol group and three in the salbutamol
group). Other common AEs were dizziness, head-
ache, fever, tremor and hypoasthaesia, each
reported once with formoterol treatment. There
were no serious AEs.
Discussion
An acute asthma exacerbation can be severe or
even fatal and therefore immediate relief from
bronchospasm is vital. Consequently, the primary
treatments for acute severe asthma in hospital
emergency departments are short-acting b2-ago-
nists, as they are effective and act rapidly. Previous
studies have shown that the long-acting b2-agonist,
formoterol has a rapid onset of effect in asthma
patients,4 similar to salbutamol.5,6 Furthermore,
there is some evidence that formoterol Turbuhaler
has a more favourable therapeutic index than
salbutamol delivered via pMDI.9 In this study,
cumulative doses of formoterol Turbuhaler (18, 36
and 54 mg) were at least as effective as salbutamol
pMDI plus spacer (800, 1600 and 2400 mg) based on
improvements in FEV1 at 15min after each dose
(15, 45 and 75min from baseline) in patients
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Table 2 FEV1 mean change from baseline.
Mean % change from baselinea (range) Mean (%) ratio form/salba
(95% conf. limits)
P-value
Formoterol Salbutamol
E15 19.1 15.1 103.5 0.42
(–8.5, 113.2) (–61.0, 81.7) (95.1, 112.7)
E45 31.4 22.8 107.0 0.16
(–1.4, 127.5) (56.6, 89.9) (97.2, 117.9)
E75 37.0 27.8 107.2 0.18
(2.1, 151.6) (56.6, 97.4) (96.8, 118.7)
Emax 51.2 36.1 111.1 0.039
(1.2, 182.4) (48.4, 97.4) (100.6, 122.8)
Eaverage 43.2 28.2 117 0.033
(5.3, 176.5) (55.0, 83.0) (100.9, 123.6)
E15; effect at 15min; E45; effect at 45min; E75; effect at 75min; Emax; maximal effect between 75 and 240min; Eaverage; area
under the curve between 75 and 240min.
aANOVA.
Figure 2 Effect of formoterol and salbutamol treatment
on (a) serum potassium levels, and (b) QTc over the first
4 h after initiation of treatment.
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presenting at the emergency department with
acute severe asthma.
For the emergency treatment of asthma with
salbutamol at home, GINA guidelines1 suggest up to
800 mg of salbutamol to be used every 20min, with
further subsequent doses depending on the severity
of asthma. For this high-dose study we chose three
inhalations administered within 1 h (a cumulative
dose of salbutamol 2400 mg), which should be an
adequate total dose for most patients with acute
severe asthma. Previous experience in patients
with stable asthma and healthy volunteers sug-
gested that a cumulative dose of formoterol 54 mg
via Turbuhaler (delivered dose corresponding to
72 mg metered dose) would be the nearest equiva-
lent dose to salbutamol 2400 mg regarding bronch-
odilation.4,8
As the study progressed, the difference in the
FEV1 observed between formoterol- and salbuta-
mol-treated patients widened. This increasing
difference in effect was significant only after the
75min time point. This difference probably re-
flected either a difference in dose/potency of the
treatments or the longer duration of action
observed with formoterol.4,17 No difference in
onset of action has been seen between the two
drugs in studies performed in stable asthma5 and
following an induced bronchospasm.6 The rapid
onset of bronchodilator effect of formoterol 4.5–
36 mg within 1–4min in stable asthma and longer
duration of action up to 12 h17 also has the
potential to improve outcomes for patients with
acute severe asthma in an emergency setting,
providing it is associated with at least as good a
safety profile as salbutamol. Insufficient response
in FEV1 to inhaled rapid- and short-acting b2-
agonists in patients with acute severe asthma may
require hospitalization and the supervision of
further doses of b2-agonists to monitor for possible
side effects.1 In this study, it was notable that the
increase in FEV1 in response to salbutamol ap-
peared to plateau soon after the last dose, whereas
FEV1 continued to improve for the duration of the
study following formoterol administration. In our
study population there were no treatment failures
and no patients required hospital admission after
the 4-h follow-up.
In addition to inducing bronchodilation, stimula-
tion of b2-adrenoceptors can result in extrapul-
monary effects. As high doses of b2-agonists may
often be required to treat acute severe broncho-
constriction, safety may become an important
consideration that dictates the dose and frequency
of administration, and therefore the use of these
agents.18 Therefore, blood pressure, heart rate,
ECG and serum potassium were monitored during
the study. There was no significant difference
between the active treatments on blood pressure,
ECG and heart rate. Formoterol significantly re-
duced average serum potassium values by more
than salbutamol. However, this difference between
treatments was not considered of clinical impor-
tance, with the lowest individual value on treat-
ment observed in the salbutamol group (Table 3).
Previous studies have shown that the systemic/
extrapulmonary effects of formoterol are similar or
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Table 3 Safety results (average values) over 4-h period following treatment.
Safety variable Mean baseline values (range) Mean treatment values (range) Difference in adjusteda
means (95% CI)
Formoterol Salbutamol Formoterol Salbutamol
Heart rate
(bpm)
93.6 (72–134) 90.5 (60–130) 94.7 (68–129) 90.1 (60–125) 2.0 (1.5, 5.5)
Systolic blood
pressure
(mmHg)
135.5 (99–203) 128.8 (100–
166)
124.8 (96–171) 120.5 (92–157) 0.8 (3.7, 5.3)
Diastolic blood
pressure
(mmHg)
83.6 (55–126) 81.1 (59–113) 75.6 (54–108) 75.2 (54–102) 0.9 (4.3, 2.5)
QTc interval
(ms)
421.4 (358–
527)
418.8 (353–
476)
428.5 (370–
523)
422.9 (342–
484)
3.6 (6.0, 13.1)
Serum
potassium
(mmol/l)
4.0 (2.9–5.3) 3.9 (3.1–4.9) 3.5 (2.8–4.3) 3.7 (2.6–4.7) 0.2** (0.4, 0.1)
QTc¼QT interval corrected for heart rate.**Po0.01.
aAdjusted mean treatment difference from ANOVA.
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less pronounced than with short-acting b2-agonists,
such as terbutaline19 or salbutamol,8 especially
when full dose–response curves for efficacy and
safety are considered.9 The doses of formoterol and
salbutamol used in this study were not equieffec-
tive. The efficacy of formoterol over 4 h was
significantly better than that of salbutamol. Con-
sequently the systemic activity measured as a
decrease in serum potassium was also significantly
greater after administration of formoterol,
although clinically not important. Furthermore,
there were no discontinuations due to AEs with
either formoterol or salbutamol during the study
and both treatments were equally well tolerated.
The efficacy of formoterol has been demonstrated
in this study based on objective lung function
assessments. However, additional subjective bene-
fits on symptoms and health-related quality of life
were apparent with both formoterol and salbuta-
mol. VAS and Acute AQLQ were both used to assess
patient’s symptoms and wellbeing subjectively.
Formoterol and salbutamol treatment caused
equally rapid improvement in symptoms by both
assessments. Both formoterol and salbutamol pro-
duced similar improvements in the symptoms and
emotional function domains of the Acute AQLQ, and
patients did not distinguish any difference in the
overall treatment evaluation. Therefore, from a
patient’s perspective, formoterol appears to be at
least as good as salbutamol at improving wellbeing.
These findings support those obtained in a recent
placebo-controlled study in patients with metha-
choline-induced bronchoconstriction, where both
formoterol and salbutamol provided early relief
from dyspnoea (Borg scale) within the first minute
after inhalation.20
While the results of this 4-h study are unlikely to
warrant a revision of guidelines for treating asthma
in an emergency setting,1 they offer reassurance
that formoterol may be used for the safe and
effective treatment of acute asthma exacerbations
at home. The clinical implications of these results
are important as many patients use formoterol for
maintenance therapy and as an alternative as-
needed therapy. This study demonstrated that
patients prescribed formoterol Turbuhaler for
regular or as-needed therapy can also obtain rapid
and effective relief of acute severe exacerbations
upon the inhalation of the maximum daily dose.
Thus, the need for patients to carry and use
another rapid-acting inhaled bronchodilator in the
case of an emergency is not supported by these
findings.
To summarize, in this study formoterol 3 18 mg
via Turbuhaler was well tolerated and at least as
effective as salbutamol 3 800 mg via pMDI plus
spacer in patients with acute severe asthma. After
75min, formoterol demonstrated significantly bet-
ter bronchodilation than salbutamol, that lasted for
4 h, which was the duration of this study.
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